A carregar...
Ruxolitinib combined with vorinostat suppresses tumor growth and alters metabolic phenotype in hematological diseases
JAK-2 dysregulation plays an important role as an oncogenic driver, and is thus a promising therapeutic target in hematological malignancies. Ruxolitinib is a pyrrolo[2.3-d]pyrimidine derivative with inhibitory activity against JAK1 and JAK2, moderate activity against TYK2, and minor activity agains...
Na minha lista:
| Publicado no: | Oncotarget |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Impact Journals LLC
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5732767/ https://ncbi.nlm.nih.gov/pubmed/29262601 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.21951 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|